Firm / Organisation

Shook, Hardy & Bacon LLP

Current View:
Also ranked in:

This content is provided by Shook, Hardy & Bacon LLP.

Chair: Madeleine McDonough
Managing Partners: Lynn Murray (Chicago), Phil Goldberg (Washington, DC), Kirk Ingebretsen (Denver), Jennise W Stubbs (Houston), William Geraghty (Miami), Eva Weiler (Orange County), Sean Wajert (Philadelphia), Amir Nassihi (San Francisco), Bart Eppenauer (Seattle), Jennifer Voss (Tampa), Simon Castley (London)
Number of partners and counsel: 293
Number of attorneys: 47

Firm Overview:
Shook, Hardy & Bacon has long been recognized as one of the premier litigation defense firms in the country. Shook has represented companies in the health, science and technology sectors in their most substantial national and international product liability, mass tort and complex litigation matters for more than 130 years. Shook’s success in these areas has captured the attention of many in the industry, including The American Lawyer, which recognized the firm as its ‘Product Liability Litigation Department of the Year’ in 2012 and 2008, as well as a finalist in its 2010 and 2016 contests. For 13 consecutive years, Shook has also been named the ‘Product Liability Defense Law Firm of the Year’ by Who’s Who Legal: The International Who’s Who of Business Lawyers; and Shook was named one of Law360’s ‘Product Liability Groups of the Year’ in 2015 and 2016. In 2018 the firm was honored to receive the Corporate Equality Index’s 100-percent rating for the 10th consecutive year.

Main Areas of Practice:
Shook is known for its abilities and expertise in litigation — more than 90 percent of its attorneys are litigators, and many have advanced degrees in health and sciences fields. The firm has represented leading international companies in a variety of industries, including phar- maceutical and medical device, technology, chemical, energy, food and beverage, and automotive. In the past three years alone, Shook lawyers have tried more than 30 cases to verdict in state and federal courts, successfully defending clients against claims involving product liability, environmental and toxic tort, patent infringe- ment, labor and employment and other claims. Shook has represented the industry’s leading pharmaceu- tical manufacturers for more than 40 years. The firm has also represented US cigarette manufacturers in product liability litigation continuously since 1957, and currently represents the largest US tobacco company as lead trial counsel in its pending litigation. In recent years, the firm has leveraged its complex litigation expertise to build substantial national practices in intellectual property, environmental and toxic tort litigation, data security and privacy, employment litigation, commercial litigation, and public policy. While product liability remains a core strength and a growth area for the firm, practice diversification has allowed Shook to offer a variety of innovative solutions to regulatory and compliance challenges as well.

Value Champions:
Some 35 to 40 percent of the firm’s work is covered by alternative fee arrangements. Shook was named a Value Champion by the Association of Corporate Counsel—the only firm to be so recognized by ACC three times—in 2012, 2013 and 2015 for working with clients on innovative, collaborative and savings-driven approaches. The firm has achieved this recognition by continually focusing on creating close partnerships and tailoring its service offerings to align with the client’s definition of value for a particular engagement.

Shook has represented nearly three-quarters of the Fortune 100. The firm’s clients include global industry leaders who demand proven legal strategies. As a result, the firm has developed long-standing relationships with many of its clients. ‘There is no short list for national counsel of a major pharmaceutical company that doesn’t include Shook’, said the former General Counsel of one of the nation’s leading pharmaceutical companies in an article on Shook. Another client added that Shook attorneys litigate like they’re going to trial, but not unnecessarily. ‘If a matter does end up going to trial, they’ll be in the best possible position to defend it’, the Shook client told the ABA Journal.